Lorcaserin hydrochloride for the treatment of obesity and overweight
 
Status Suspended
Process STA
Referral date 01 June 2010
Topic area
  • Endocrine, nutritional and metabolic
  • Public health

Provisional Schedule

Closing date for invited submissions / evidence submission: 15 February 2013
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC

Project Team

Communications manager: Alice Law
Executive Lead: Andrew Dillon
Project manager: Kate Moore
Technical Lead: Grace Jennings

Consultees

Manufacturers/sponsors Arena Pharmaceuticals (lorcaserin hydrochloride)
Others Department of Health
  Staffordshire PCT Cluster
  Welsh Assembly Government
Patient/carer groups Beat
  HEART UK
  National Obesity Forum
  Weight Concern
Professional groups Association of British Clinical Diabetologists
  National Diabetes Nurse Consultant Group
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  The Obesity Management Association

Commentators

Associated guideline groups None
Associated public health groups None
Comparator manufacturers GlaxoSmithKline (orlistat) (confidentiality agreement not signed, not participating)
  Roche Products (orlistat)
Evidence Review Group National Institute for Health Research Health Technology Assessment Programme
  School of Health & Related Research Sheffield (ScHARR)
General Commissioning Support Appraisals Services
  Department of Health,Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency

Timeline

Key events during the development of the guidance:

Date Update
22 May 2013

NICE has been informed by the sponsor, Arena Pharmaceuticals, that they have withdrawn their licensing application for the above indication. The company is currently evaluating the best approach for submitting at a later date. Therefore this topic has now been suspended. We will continue to monitor any development and update you if the situation changes.

03 May 2013

Following an update on the regulatory status of this technology from the manufacturer, the discussion of this appraisal at the Committee meeting on 30 May 2013 has been cancelled.

We will update you with more information in due course.

23 July 2012

Following on from advice received from the manufacturer, this appraisal has now been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early December 2012. The deadline for submissions is expected in approximately mid February 2013.

02 November 2011

Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid October 2012. The deadline for submissions is expected in approximately mid December 2012.


For further information on how we develop guidance, please see our page about NICE technology appraisal guidance